What Repeated Eye Injections Actually Cost, and What You’ll Really Pay
The Cost of Repeated Eye Injections at a Glance
Before the money, the safety. Call your retina clinic the same day, and do not wait for your booked visit, if in the hours or days after an injection you notice any of these:
- Eye pain that is getting worse, not settling
- Vision that is getting worse rather than clearing
- Redness that spreads across the eye
- New, heavy light sensitivity
- A shower of new floaters, or flashing lights
Most of these calls turn out to be ordinary soreness. Serious infection is rare. In one pooled review, infection inside the eye was found in 144 of 510,396 injections, about 1 in every 3,5441. So the odds are on your side. But it is treated best when it is caught early, so make the call anyway. No clinic will mind. Cost is never a reason to sit on a symptom like these, and the rest of this page is about making the money part easier to face.
Your share is usually a fraction of the sticker price, and the single biggest lever is which drug goes in the syringe. Under Original Medicare in 2026 you pay a $283 annual Part B deductible, then 20 percent of the Medicare-approved amount for each covered service or item, and Original Medicare has no annual cap on what you can owe2. As of October 2022, the Medicare average sales price of one dose of aflibercept 2 mg was $1,806, and of ranibizumab 0.5 mg was $1,2923. Twenty percent of those 2022 prices is roughly $260 to $360 per injection, before any secondary insurance. Treat that as the scale, not a quote, since drug prices move between years. It is also the number a supplemental plan, a different drug choice or an assistance program can change most.
An eye injection is not one line item, which is why quoted prices vary so wildly. There is the drug, which is far the largest piece. There is a fee for the injection procedure. There is often a separate charge for the office visit and for retina imaging the same day. Ask the billing office to show all three together. If you are quoted one number by phone, ask whether it includes the drug, because that is usually the piece left out.
Four things move your number, and none of them is your diagnosis: which drug is used, what insurance you carry, how many injections you need in a year, and whether you have met your deductible yet. Two people in the same waiting room, treated for the same condition on the same day, can owe amounts that differ by thousands of dollars a year.
What These Injections Are and What They Do
Anti-VEGF medicine blocks VEGF, a signal that drives leaking abnormal blood vessels in the retina, which reduces that leaking, slows or stops the damage those vessels cause, and slows down vision loss4. VEGF stands for vascular endothelial growth factor, a protein that tells new blood vessels to grow. In a healthy eye that is useful. In these conditions it is the problem. The medicine does not repair damage already done, which is its honest limit, and it is why the schedule matters more than any single dose.
Anti-VEGF injections are used for wet age-related macular degeneration, macular edema meaning swelling of the central retina, diabetic retinopathy and retinal vein occlusion4. Those are different diseases with different schedules and different total costs, so a friend's bill for one of them tells you very little about yours. If you are budgeting, budget for your own condition and your own eye. Ask your retina specialist which of these you are being treated for, because the paperwork often uses the clinical name rather than the plain one.
The procedure itself is quick, which surprises most people the first time. Your ophthalmologist cleans the eye to lower the risk of infection, numbs the eye to reduce pain, may place a small device to hold your eyelids out of the way, and injects the drug through the white of the eye with a very thin needle, and the injection itself takes only a few seconds4. Most of the appointment is checking, imaging and waiting. Plan for an hour or two even though the needle part is over in seconds.
How Many Injections to Budget For
The first year is usually the most expensive one, and knowing that in advance helps. One cost analysis built on a diabetic macular edema trial described these medicines as given 9 to 11 times in the first year of treatment, and on average 17 times over 5 years5. That figure comes from a single analysis of a single condition, so read it as a rough planning yardstick rather than a schedule for every diagnosis. In Original Medicare claims from 2011 to 2015, ranibizumab and aflibercept each averaged 4.8 injections per patient per year across everyone treated6. Those differ because one is a trial-based figure and the other is real-world practice, including people who started or stopped mid-year. Ask your own clinic what it expects for your eye.
Treatment is often front-loaded, though that is a pattern rather than a rule. In that same diabetic macular edema cost analysis, the figures used were 9 to 11 injections in the first year and an average of 17 over 5 years5. Put side by side, those two numbers work out to fewer injections per year after the first, but the analysis does not track what any one person ends up needing, and it does not cover the other conditions treated this way. Many retina specialists stretch the interval gradually while watching your scans. Ask your own doctor whether your plan is expected to follow that shape.
This is the part worth saying plainly. Your ophthalmologist decides how many treatments you need based on how your eye responds to the medicine4, and the interval is set to hold the leaking down rather than to fill the calendar. Quietly skipping an appointment saves the coinsurance and does not hold the disease. Say the cost problem out loud to your clinic instead. A schedule change made with your doctor is a very different thing from one made by not showing up.
The Drug Choice Is the Biggest Price Lever
The gap is not a few percent. It is orders of magnitude.
| Drug | Price per dose, and the date of that price |
|---|---|
| Aflibercept 2 mg (Eylea) | $1,806 Medicare average sales price, October 2022 |
| Ranibizumab 0.5 mg (Lucentis) | $1,292 Medicare average sales price, October 2022 |
| Bevacizumab 1.25 mg (Avastin), compounded | About $60 wholesale, 2015 |
In 2015 wholesale prices a dose of aflibercept cost $1,850 and a dose of ranibizumab 0.3 mg cost $1,170, while a compounded dose of bevacizumab cost about $60, making the two branded drugs roughly 31 and 20 times more expensive5. Bevacizumab is used in the eye off-label, meaning it is not FDA-approved for this use, and a compounding pharmacy repackages it into eye-sized doses. Many retina practices use it routinely. Ask which drug is planned for you and why, because the reasoning and the price both belong in that conversation.
Biosimilars are highly similar follow-on versions of a biologic drug, made once the original loses exclusivity. In a published cost model, the ranibizumab biosimilars carried wholesale prices of $816 for the 0.3 mg dose and $1,130 to $1,360 for the 0.5 mg dose, against a $1,292 Medicare average sales price for branded ranibizumab 0.5 mg as of October 2022, and no aflibercept biosimilar was on the market at that point; the same model estimated that switching from ranibizumab and aflibercept to their respective biosimilars could potentially lead to total cost savings of about $33.6 million for patients3. That saving is a modeled national total, not a forecast of your own bill, and the listed prices are discounts off a high price rather than the drop from roughly $1,800 to roughly $60 that bevacizumab represents. The market has moved since 2022, so ask for current pricing.
Three questions get you most of the way. Which drug are you planning to use, and is a lower-cost option clinically reasonable for my eye? What will my share be per injection after insurance? How many injections should I expect in the first year? If you are told the second cannot be answered until the claim processes, ask for the billing code and the drug name, then call your insurer yourself.
How Medicare and Other Insurance Pay for This
Eye injections are given in a clinic, so they fall under Part B rather than the drug benefit. In 2026 the Part B annual deductible is $283, after which you pay 20 percent of the Medicare-approved amount for each covered service or item, and Original Medicare Parts A and B have no annual out-of-pocket limit2. That missing cap is the structural problem for anyone facing a long course of injections, and it is the gap supplemental coverage exists to close.
Supplemental coverage is usually the difference between a manageable year and an alarming one. Medigap policies provide wraparound coverage for Medicare Part A and Part B costs, and for 2026 Medigap plan K carries an $8,000 out-of-pocket maximum while plan L carries a $4,000 maximum2. You typically pay the Part B premium, $202.90 a month in 2026, whether you are in traditional Medicare or a Medicare Advantage plan7. Medicare Advantage plans set their own copays and networks, so check that your retina specialist is in network before switching.
Ask, because none of these are offered automatically. Through the Medicare Savings Programs, state Medicaid programs help cover Medicare premiums, and often deductibles and coinsurance, for Medicare beneficiaries with low incomes and modest assets7. Beyond that, ask the clinic's billing office three questions: does the drug maker run a patient assistance or copay program, is there a charitable copay foundation covering your diagnosis, and does the practice have its own financial assistance policy. Ask again each year, since eligibility and funding change.
The Medicare figures above do not describe you. Working-age people are usually covered commercially, where the drug sits under a medical benefit with its own deductible, coinsurance and prior-authorization rules. With no coverage at all, ask about the lowest-cost drug option, the practice financial assistance policy, and a payment plan. Ask before the first injection, not after the first bill.
Who These Injections Are For, and Who Should Wait
Candidacy is about the disease in your retina, not about your budget. These injections are used when leaking abnormal vessels or swelling in the retina is driving vision loss, in wet age-related macular degeneration, macular edema, diabetic retinopathy and retinal vein occlusion4. Your retina specialist decides from your scans and your vision, not a checklist you can apply at home. What you can bring is honesty about what you can afford to sustain, because a plan you keep is worth more than a better plan you abandon in March.
An injection is put off when the eye or the person is not in a safe state for it. The eye is cleaned before every injection to lower the risk of infection4, which is why an active infection in or around the eye matters so much. Tell your clinic before the appointment if you have an infection anywhere, if the eye is red or sore for another reason, if you have reacted to the drug or the cleaning solution before, if you take blood thinners, or if you are pregnant or planning to be. Postponing is your doctor's call, not something to arrange by cancelling.
For some conditions there are other options, including laser treatment, steroid implants or a different injection schedule, and for others there are not. What fits depends on which condition is being treated, since these injections span wet age-related macular degeneration, macular edema, diabetic retinopathy and retinal vein occlusion4. Ask what the alternatives are for your diagnosis and how they compare over a year. A less frequent option can cost more per visit and less per year.
What to Expect at the Visit and Afterwards
Two things belong in this conversation that people usually leave out. Ask whether imaging is billed separately at each visit, since that quietly changes the yearly total. And if you are in a Medicare Advantage plan, ask whether prior authorization is needed and how long it usually takes, because delays there push appointments back.
Clinics generally warn about the same short-lived things: a scratchy feeling as the numbing wears off, a red patch where the needle went in, some new floaters, and blurred vision for the rest of the day from the cleaning solution and dilating drops. Arrange a ride home for at least the first one. Use any drops exactly as your clinic instructs, and do not rub the eye that day.
Most people are back to ordinary activity the next day. Driving on the day of the injection is a bad idea because of the dilation and blur, so plan the appointment around that rather than your work calendar. Practices differ on pools, hot tubs and dusty work, so ask your own clinic for its instructions and follow those over anything you read here.
Risks, and the Realistic Long View
This is the risk that matters, and the numbers are genuinely small. Infection inside the eye after an anti-VEGF injection (clinical: endophthalmitis) occurred in 52 of 105,536 injections in one pooled analysis, about 1 in every 2,030, in 197 of 350,535 in another, about 1 in every 1,779, and in 144 of 510,396 injections across 20 large series, about 1 in every 3,5441. Read the other side too. In that pooled series, about 3,543 of every 3,544 injections passed without it. It is rare, it is treatable when caught early, and knowing the warning signs is what makes early possible.
The frequent problems are the small ones. A red blotch on the white of the eye is bleeding under the surface membrane. It looks alarming and it clears on its own without treatment. Grittiness, watering and mild soreness are usual, and new floaters usually settle. None of these needs an urgent call on its own. What changes that is pain, or vision getting worse rather than better, which is the next section.
Plan for a course of treatment rather than a single bill. In the diabetic macular edema cost analysis, treatment averaged about 17 injections over 5 years5, and while that single-condition figure will not match every diagnosis, it shows why the arithmetic that matters is your per-injection share multiplied across a year, then repeated. The scale of this is not unique to you. One Academy analysis reports that aflibercept and ranibizumab account for about 12 of every 100 dollars of the Medicare Part B budget6. That is why coverage rules and drug choice keep shifting, and why it is worth re-asking about your options each year.
When to Call Your Eye Doctor
Call your retina specialist right away, on the same day, if in the hours or days after an injection you have increasing eye pain, vision that is getting worse rather than settling, a spreading redness, or new heavy light sensitivity. In a pooled review, infection inside the eye after an injection often presented earlier than infection after cataract surgery, and the review calls it a potentially devastating complication1. Most such calls turn out to be ordinary soreness. Making the call anyway is right, because the rare case is the one where hours count.
A fading red patch, mild grittiness, or a few new floaters that settle are worth mentioning at your next visit rather than phoning at midnight. The same goes for scheduling questions. If your vision drifts between appointments, though, call and say so rather than waiting for the booked date, since the interval may need adjusting.
The billing office, not the clinical staff, and sooner rather than later. Ask for an itemized statement, check that the drug, the injection and the visit are each billed once, and ask what financial assistance the practice offers. If part of it was denied, ask for the denial reason code and whether the practice will appeal. Bills get harder to fix once they leave the practice.
Common Questions About Paying for Eye Injections
Usually because a different drug is being used. In 2015 prices, aflibercept and ranibizumab cost roughly 31 and 20 times more than compounded bevacizumab5. Facility type matters too, since a hospital outpatient department often bills differently from a physician office. Ask both clinics which drug they plan to use and which setting the injection happens in. Those two answers explain most price differences you will find.
Yes, as a Part B service, with cost sharing rather than full payment. In 2026 you pay the $283 Part B annual deductible, then 20 percent of the Medicare-approved amount for each covered item or service2. The drug and the injection are both covered items, so both carry that 20 percent share. Coverage rules and the amounts change annually, so confirm the current year's figures with Medicare or your plan rather than relying on a figure you read once.
That is a clinical question for your retina specialist about your eye, and this page cannot answer it for you. What is fair to say is that the price gap is far larger than any difference in how the drugs are given: the branded drugs cost roughly 20 to 31 times what compounded bevacizumab cost in 2015 prices5. Ask your doctor directly whether a lower-cost option is reasonable for your condition, and ask what would make them change drugs later.
Tell the clinic why, rather than simply not attending. How many treatments you need is decided by your ophthalmologist, based on how your eye responds to the medicine4, so a gap taken silently is a gap nobody has accounted for. Clinics can often move an appointment, switch drugs, start an assistance application or set a payment plan. None of that can happen if the first they hear of the problem is a missed appointment.
Possibly, though nobody can quote you a figure for your own bill. One published cost model estimated that switching from ranibizumab and aflibercept to their respective biosimilars could potentially lead to total cost savings of about $33.6 million for patients3. That is a projection spread across everyone treated, not a measured saving on any one statement. What your share turns on is more immediate: which drug your clinic uses, and what supplemental coverage you carry. Ask at your next visit whether a biosimilar is being used for you.
Usually yes, and it is a reasonable thing to insist on. Ask the practice for a written good-faith estimate that separates the drug, the injection procedure and any imaging, and ask which billing codes it uses. Then call your plan with those codes and ask what your share will be. It takes two phone calls. It is far easier than disputing a bill that has already been issued, and it lets you raise cost concerns while the plan is still being made.
More Questions About Costs and Coverage
Because Original Medicare was not built with one. The Medicare out-of-pocket maximum does not apply to Original Medicare Parts A and B, which has no annual out-of-pocket limit2. That is precisely why supplemental coverage matters so much for a treatment given many times a year. Medigap plans provide wraparound coverage for Part A and Part B costs, and for 2026 plan K carries an $8,000 out-of-pocket maximum and plan L a $4,000 maximum2. Review your supplemental options during open enrollment rather than mid-treatment.
Take your expected share per injection and multiply. In one diabetic macular edema cost analysis, first-year treatment was 9 to 11 injections5, while real-world Original Medicare claims from 2011 to 2015 averaged 4.8 injections per patient per year6. Neither figure is a forecast for your eye or your condition. Ask your clinic what it expects for you, then add the annual deductible and any separate imaging charges. Build the estimate with your billing office rather than alone, since they know which codes your visits generate.
Yes, because the drug is the dominant cost and each eye needs its own dose. Two eyes treated on the same day usually means two drug charges and two injection fees, though you may pay only one office-visit charge. Ask your billing office how they bill bilateral injections, since practices and payers differ in how they apply reductions. If cost is the obstacle, say so, and ask whether the eyes can be staggered or whether a lower-cost drug is reasonable for you.
Sometimes, though continuity of care has real value. The two things worth comparing are the drug used and the billing setting, since a hospital outpatient department and a physician office often bill the same injection differently. Weigh that against the cost of leaving a specialist who knows your scans. If you do move, ask the original practice to send your imaging, and expect the new clinic to want its own baseline scans.
- Which drug are you planning to use for me, and why that one?
- Is a lower-cost drug clinically reasonable for my condition?
- How many injections should I expect in the first year, and after that?
- What will my share be per injection under my plan?
- Are the imaging and the office visit billed separately each time?
- Is a biosimilar being used for me, and what does it change about my cost?
- Who do I call if I cannot afford the next appointment?
- What symptoms after an injection should make me call you the same day?
- International Journal of Retina and Vitreous / NCBI PMC5088471, review pooling 20 large series together with two published meta-analyses of anti-VEGF injection series (2016). Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.
- National Council on Aging, benefits guidance compiled from the published CMS 2026 Medicare Parts A and B premium and deductible figures (2026). What You'll Pay in Out-of-Pocket Medicare Costs in 2026.
- EyeNet Magazine, American Academy of Ophthalmology, reporting a cost model built on Medicare Part B allowable-payment data from October 2022 and published market-share claims data (2023). Intraocular Bevacizumab Biosimilar May Not Be Cost-Effective.
- EyeSmart patient education, American Academy of Ophthalmology (2025). Anti-VEGF Treatments.
- Ophthalmology / NCBI PMC6648661, cost-effectiveness analysis of the DRCR Network Protocol T multicenter randomized trial, using 2015 wholesale acquisition costs from Red Book Online (2016). Cost-Effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema: Analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
- EyeNet Magazine, American Academy of Ophthalmology, reporting an analysis of Original Medicare Part B claims for 2011 to 2015 (2017). Medicare Part B Spending and Anti-VEGF Drugs.
- KFF (Kaiser Family Foundation), health policy analysis of Medicare beneficiary cost trends (2026). Medicare Beneficiaries Are Not Insulated from Affordability Challenges As Part B Premiums Rise in 2026.